# Ascend Global Investments

> Ascend Global Investments is a VC fund backing Therapeutics and Biotechnology. See 1 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 1
- Last investment: Nov 2020
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://agi-llc.com

Ascend Global Investments is a private investment partnership that draws on family capital and select institutions to make direct investments. The firm's approach, primarily as a principal rather than as an asset manager, provides us the flexibility to invest across a broad range of differentiated opportunities and innovative structures forsignificant value creation.It was founded in 2007 and headquartered in New York, United States.We leverage the expertise and creativity of our team combined with our global network to generate superior risk-adjusted returns for our investors. AGI’s unique C-Suite Partnership works with experienced executives to acquire and build leading companies in the lower middle market. We do so by partnering with strong management teams who care who their capital partner is and who have meaningful economic stakes in the success of their businesses. We work diligently with our management teams to help them formulate strategic, financial, and operational plans that drive growth and enhance profits.

## Contacts

5 contacts available for Ascend Global Investments. Shizune tracks 4 team members at Ascend Global Investments. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ascend-global-investments-llc?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |
| Health Diagnostics | 1 | 100% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Shawn Pelsinger | Advisor | 0 | https://shizune.co/investors/profile/shawn-pelsinger |
| David Acharya | Partner | 0 | https://shizune.co/investors/profile/david-acharya |
| Robert A. Kennedy | Partner | 0 | https://shizune.co/investors/profile/robert-a-kennedy |
| Shaun Gordon | Founder and Managing Partner | 0 | https://shizune.co/investors/profile/shaun-gordon |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Prometheus Biosciences | Prometheus Biosciences, Inc., former Prometheus Laboratories, Inc., a specialty pharmaceutical company, engages in developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. It markets and promotes Entocort EC, a glucocorticosteroid, which is indicated for the induction and maintenanceof clinical remission in mild to moderately active Crohn's disease involving the ileum and/or the ascending colon. It has an agreement to acquire rights to LOTRONEX tablets, which is used in female patients with diarrhea-predominant irritable bowel syndrome; and an agreement to develop and commercialize COLAL-PRED, a development-stage product for the treatment of gastrointestinal diseases or other applications. The company also sells other branded drugs, including Imuran for use as an adjunct for the prevention of rejection in kidney transplantation and the management of active rheumatoid arthritis, Helidac Therapy for use together with an H2 antagonist for the eradication of helicobacter pylori bacteria, and Ridaura for the management of rheumatoid arthritis. In addition, Prometheus Laboratories sells a generic formulation of mercaptopurine, which is approved as maintenance therapy for acute lymphatic leukemia as part of a combination regimen through third-party distributors. Further, it provides diagnostic testing services, including specific immunoassays to detect and differentiate diseases, pharmacogenetic testing, and drug metabolite monitoring; and tests that assist physicians in using and monitoring thiopurine drugs and the detection, diagnosis, or treatment of celiac disease, lactose intolerance, and other related disorders. Prometheus Laboratories, Inc. was founded in 1995 and is headquartered in San Diego, California. | $130M | Private Equity | Nov 09, 2020 |  |

1 of 1 investments shown.

## Co-investors
- [Ascend Capital Group](https://shizune.co/investors/profile/ascend-capital-group) — VC Fund, 1 deal together
- Cedars Sinai — VC Fund, 1 deal together
- [Cormorant Capital](https://shizune.co/investors/profile/cormorant-capital) — VC Fund, 1 deal together
- Cowen Healthcare Investments — VC Fund, 1 deal together
- Eventide — VC Fund, 1 deal together
- [Irving Investors](https://shizune.co/investors/profile/irving-investors) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Foresight Group](https://shizune.co/investors/profile/foresight-group) — VC Fund
- [YFM Equity Partners](https://shizune.co/investors/profile/yfm-equity-partners) — VC Fund
- [Fondaction](https://shizune.co/investors/profile/fondaction) — VC Fund

## FAQ

### What does Ascend Global Investments invest in?

Ascend Global Investments invests primarily in Therapeutics, Biotechnology and Pharmaceutical startups, most often at Private Equity stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Ascend Global Investments?

Public channels for Ascend Global Investments include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Ascend Global Investments?

The team at Ascend Global Investments includes Shawn Pelsinger (Advisor), David Acharya (Partner) and Robert A. Kennedy (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co